Meta-Analysis Of The Association Between RASSF1A Promoter Methylation And Ovarian Cancer

Purpose:RAS-associated domain family 1A(RASSF1A)gene is one of tumor suppressor genes(TSG).Abnormal methylation of TSG is an important epigenetic silencing mechanism in the development of ovarian cancer.The methylation of RASSF1 A gene promoter was closely related to the occurrence and development of ovarian cancer(OC).However,due to the small sample size,diversity of sample sources and methylation detection methods in many studies,there is still no unified conclusion.The purpose of this study was to investigate the relationship between promoter methylation of RASSF1 A gene and the risk of ovarian cancer,as well as the clinical stage,pathological type,pathological differentiation,age,lymph node metastasis and serum CA125 of ovarian cancer.Methods:Comprehensive search Pub Med,EMBASE,the Cochrane,ten thousand party and hownet database,in strict accordance with the literature and exclusion criteria,collecting between January2000 and December 2020 the RASSF1 A gene promoter methylation and ovarian cancer risk and its clinical stage,pathological classification and related research,and apply the Newcastle Ottawa scale(NOS)to assess the quality of these studies,and eligible studies were determined.Contrast in patients with ovarian cancer and ovarian cancer tissue,blood,such as RASSF1 A gene promoter methylation status of the difference between,at the same time comparing different clinical main pathological variables such as,age,clinical stage,pathological type and pathological differentiation,lymph node metastasis,and serum CA125 in patients with ovarian cancer incidence of RASSF1 A gene promoter methylation differences.Odds ratio(OR)was used as an estimate of relative risk.The confidence interval(CI)is expressed as a 95% interval.Then use Rev Man 5.3 software for data processing and analysis.Results:Through screening and evaluation,this study finally into 27 references,literature published the year for 2001-2019,including 21 study explores happen RASSF1 A gene promoter methylation of the correlation between frequency and risk of ovarian cancer,17 studies evaluating happened RASSF1 A gene promoter methylation of frequency and the relationship between the ovarian tumor stage.There were 1858 cases of primary ovarian cancer and 888 cases in the control group(including benign ovarioma and normal ovaries).The frequency of methylation of the RASSF1 A gene promoter was significantly higher in ovarian cancer patients than in controls.In ovarian cancer,the frequency of methylation of the RASSF1 A gene promoter was not significantly associated with clinicopathologic features.Conclusion:The results showed that the methylation of the RASSF1 A gene promoter was positively correlated with the risk of ovarian cancer,suggesting that the occurrence of ovarian cancer was closely related to the methylation of the RASSF1 A gene promoter.RASSF1 A promoter methylation was not associated with clinical stage,pathological type,tumor grade,lymph node metastasis,and age,suggesting that RASSF1 A promoter methylation was not associated with the progression and prognosis of ovarian cancer.A significant association was observed between RASSF1 A promoter methylation and serum CA125 in ovarian cancer patients(OR=3.22,95%CI1.60-6.48,P=0.001).Thus,RASSF1 A gene promoter methylation may have strong potential as a marker of ovarian cancer susceptibility.